• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

How Health Policy Can Impact Adoption for Adalimumab Biosimilars


In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.

"When Choice Arrives: Competition & Consequences" written over a bright blue syringe with the AJMC/The Center for Biosimilars logo in the bottom right corner. Under the image is a list of 6 items (4 article titles and 2 podcasts). The second podcast item is highlighted.

Readers can also check out part 1, part 2, part 3, part 4, and podcast 1 now.

Starting in January next year, the United States will welcome up to 10 adalimumab biosimilars referencing Humira, one of the most profitable drug in the world. Currently, there are several barriers to uptake to biosimilars, including payer and pharmacy benefit manager interference with formulary placement, misaligned incentives that favor prescribing the reference product over biosimilars, and reference manufacturer-led anti-competitive practices preventing biosimilar market entry. However, there are a number of policy and procedural efforts being put in place by congressional leaders, the FDA, and HHS the could help to boost biosimilar uptake and give adalimumab biosimilars a real chance to gain market share.

Today, I’m joined by Julie Reed, executive director of the Biosimilars Forum, a nonprofit organization aimed at the advancement of biosimilar adoption through collaboration with biosimilar manufacturers. Prior to her work with the Forum, she served as vice president and global corporate affairs lead of immunology, inflammation, and biosimilars at Pfizer and she is a staunch advocate for biosimilar adoption and the advancement of biosimilar legislation, including President Biden’s 2021 executive order on increasing competition in the pharmaceutical sector and the Biosimilars User Fee Amendment III, also known as BsUFA III. Our conversation today will focus on how federal policies could shape the adalimumab market next year and what congressional leaders can do now to help the process.

Show notes

This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars.

To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here.

To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here.

To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here.

To read part 4 of this series, "How Payers Can Prepare for Adalimumab Biosimilars," click here.

To listen to the other podcast in this series, “What Will Year 1 Look Like for Adalimumab Biosimilars?” click here.

Related Videos
Ha Kung Wong, JD.
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Stephen Hanauer, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.